1314580-75-0Relevant academic research and scientific papers
Optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitors of heat shock protein 90. Identification of development candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1h- pyrazol-1-yl)ethoxy]-6-methylphenyl}-n-(2,2-difluoropropyl)-5, 7-dihydro-6h-pyrrolo[3,4-d]pyrimidine-6-carboxamide
Zehnder, Luke,Bennett, Michael,Meng, Jerry,Huang, Buwen,Ninkovic, Sacha,Wang, Fen,Braganza, John,Tatlock, John,Jewell, Tanya,Zhou, Joe Zhongxiang,Burke, Ben,Wang, Jeff,Maegley, Karen,Mehta, Pramod P.,Yin, Min-Jean,Gajiwala, Ketan S.,Hickey, Michael J.,Yamazaki, Shinji,Smith, Evan,Kang, Ping,Sistla, Anand,Dovalsantos, Elena,Gehring, Michael R.,Kania, Robert,Wythes, Martin,Kung, Pei-Pei
, p. 3368 - 3385 (2011)
Figure Presented. A novel class of heat shock protein 90 (Hsp90) inhibitors was discovered by high-throughput screening and was subsequently optimized using a combination of structure-based design, parallel synthesis, and the application of medicinal chemistry principles. Through this process, the biochemical and cell-based potency of the original HTS lead were substantially improved along with the corresponding metabolic stability properties. These efforts culminated with the identification of a development candidate (compound 42) which displayed desired PK/PD relationships, significant efficacy in a melanoma A2058 xenograft tumor model, and attractive DMPK profiles.
